#152691

Anti-Collagen Type VII [LH7.2]

Cat. #152691

Anti-Collagen Type VII [LH7.2]

Cat. #: 152691

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-4 weeks

Target: Collagen Type VII

Class: Monoclonal

Application: ELISA ; IHC ; IF ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Irene Leigh

Institute: Cancer Research UK, London Research Institute: Lincoln's Inn Fields

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-Collagen Type VII [LH7.2]
  • Clone: LH7.2
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Molecular weight: 250 kDa
  • Reactivity: Human
  • Host: Mouse
  • Application: ELISA ; IHC ; IF ; WB
  • Description: Type VII Collagen is found in anchoring fibrils at the dermal-epidermal junction. Type VII collagen is defective in Recessive Dystrophic Epidemolysis Bullosa (RDEB). LH7.2 can be used for differentiating invasive from non-invasive melanoma through clear visualisation of appearance and integrity of epidermal basement membrane and diagnosis and antenatal diagnosis of RDEB. LH 7:2 recognizes an EBM antigen which may be important in the pathogenesis of RDEB.
  • Immunogen: Cells from a single cell suspension of epidermal cells (obtained from fresh human neonatal foreskin) were lysed with Nonidet P40 in phosphate buffered saline and the insoluble pellet was sonicated to prepare insoluble fractions. The epitope is on the NC1 domain.
  • Isotype: IgG1 kappa
  • Myeloma used: Sp2/0-Ag14

Target Details

  • Target: Collagen Type VII
  • Molecular weight: 250 kDa
  • Target background: Type VII Collagen is found in anchoring fibrils at the dermal-epidermal junction. Type VII collagen is defective in Recessive Dystrophic Epidemolysis Bullosa (RDEB). LH7.2 can be used for differentiating invasive from non-invasive melanoma through clear visualisation of appearance and integrity of epidermal basement membrane and diagnosis and antenatal diagnosis of RDEB. LH 7:2 recognizes an EBM antigen which may be important in the pathogenesis of RDEB.

Applications

  • Application: ELISA ; IHC ; IF ; WB

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Eldardiri et al. 2012. Tissue Eng Part A. 18(5-6):587-97. PMID: 21939396.
  • Wound contraction is significantly reduced by the use of microcarriers to deliver keratinocytes and fibroblasts in an in vivo pig model of wound repair and regeneration.
  • Al-Refu et al. 2011. Clin Exp Dermatol. 36(1):63-8. PMID: 20637030.
  • Immunohistochemistry of ultrastructural changes in scarring lupus erythematosus.
  • Watson et al. 2001. J Invest Dermatol. 116(5):672-8. PMID: 11348454.
  • A short-term screening protocol, using fibrillin-1 as a reporter molecule, for photoaging repair agents.
  • Shimizu et al. 1990. Br J Dermatol. 122(5):577-85. PMID: 2354110.
  • Epidermolysis bullosa acquisita antigen and the carboxy terminus of type VII collagen have a common immunolocalization to anchoring fibrils and lamina densa of basement membrane.